Zhitong Finance App News, Rundu Co., Ltd. (002923.SZ) issued an announcement. The company recently received the “Notice of Approval of the Marketing Application for Chemical Ingredients” for levodipine benzenesulfonate issued by the State Drug Administration. The drug is indicated for the treatment of high blood pressure and angina pectoris. The company has now obtained a notice of approval for the marketing of levamlodipine benzenesulfonate APIs, further improving the company's product layout in the field of cardiovascular and cerebrovascular treatment, enriching the company's product matrix, helping to enhance overall market competitiveness and in line with the company's development strategy.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.